Stocks extend losses as virus aid languishes in Congress

  • In this photo provided by the New York Stock Exchange, traders Edward McCarthy, left, and Robert Charmak work on the floor during the Delwinds Insurance Acquisition Corp. IPO, Friday Dec. 11, 2020. U.S. stocks fell in morning trading Friday as prospects for another aid package from Washington faded while a surge in virus cases threatens to inflict more damage on an already battered economy. (Colin Ziemer/New York Stock Exchange via AP)

NEW YORK — U.S. stocks fell in afternoon trading Friday as prospects for another aid package from Washington faded while a surge in virus cases threatens to inflict more damage on an already battered economy.

Investors have been hoping for another financial lifeline to help cushion the latest blow from COVID-19 to people, businesses and state governments. However an emerging $900 billion aid package from a bipartisan group of lawmakers has essentially collapsed because of continued partisan bickering.

The S&P 500 fell 0.7%, further backing off the record high it set on Tuesday. It is now on track for a 1.5% dip this week after two weeks of solid gains. The Dow Jones Industrial Average fell 76 points, or 0.3%, to 29,923 as of 12:56 p.m. Eastern time. The Nasdaq shed 1%.

Technology companies and banks led the decline. Apple fell 1.5% and Bank of America slipped 2.4%. Investors sought shelter in less risky holdings. Utilities, real estate companies and makers of essential consumer products held up better than the rest of the market.

Bond yields fell slightly. The yield on the 10-year Treasury edged lower to 0.88% from 0.89% from late Thursday.

Disney jumped 13.5% after giving investors an encouraging update on subscriber growth and future plans for its Disney Plus streaming service.

Stocks have been climbing over the last few weeks as advances in vaccine development raised hopes that the pandemic could be tamed in the coming months and set the global economy on a path to normalcy.

“The excitement over the vaccine has already been priced in and the market is fairly overbought, based on where we are in the economy right now,” said Kenny Polcari, managing partner at Kace Capital Advisors.

The U.K. has already started vaccinating people with Pfizer and BioNTech’s vaccine. A U.S. government advisory panel on Thursday endorsed widespread use of that vaccine, putting the country just one step away from launching an epic vaccination campaign against the outbreak that has killed close to 300,000 Americans.

Widespread vaccination will take months and the virus pandemic is prompting tighter restrictions on businesses. An already slow economic recovery appears to be stalling in the wake of the latest surge and unemployment is rising.

Polcari said markets are simply churning and consolidating following a strong November and he expects that to continue through December as stimulus talks continue. Wall Street is also waiting for a special election in Georgia in early January, which could potentially switch the balance of power in the U.S. Senate.

European stocks slipped over the increased possibility that the U.K. and the European Union will fail to strike a deal on a new economic relationship heading into next year. Britain left the EU on Jan. 31 but has continued to follow the trading bloc’s rules during a transition period that lasts until the end of the year. A no-deal split would bring overnight tariffs and other economic barriers that would hurt both sides.

Germany’s DAX fell 1.4%, and France’s CAC 40 slipped 0.8%. The FTSE 100 in London shed 0.8%. Markets in Asia ended mixed.


Your email address will not be published. Required fields are marked *


By participating in online discussions you acknowledge that you have agreed to the TERMS OF SERVICE. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. To report comments that you believe do not follow our guidelines, send us an email.